-
Achieved record annual sales exceeding $1 billion for the first time, supported by year-over-year growth across all three reporting segments.
-
Attributed strong Human Nutrition and Health performance to the ‘better-for-you’ consumer shift toward nutrient-dense, high-protein, and low-sugar food formulations.
-
Mitigated global trade and tariff volatility through a localized manufacturing model where approximately 85% of products are sold in the region of production.
-
Expanded international market presence significantly, with more than half of the company’s 2025 sales growth originating from markets outside the United States.
-
Leveraged strategic marketing partnerships with the New York Jets and Bayern Munich to reposition choline and K2 vitamins for adult cognition and women’s health.
-
Maintained operational consistency marking the 26th consecutive quarter of year-over-year adjusted EBITDA growth through disciplined execution.
-
Advanced sustainability initiatives, surpassing the 2030 greenhouse gas emission reduction goal early with a 31% reduction against the 2020 baseline.
-
Commenced construction of a state-of-the-art microencapsulation facility in New York to support future growth in food ingredients and nutraceuticals.
-
Anticipates results from over 20 active clinical studies in 2026, including high-dose choline research potentially linked to adult cognition and Alzheimer’s delay.
-
Plans to launch a ‘beauty-from-within’ marketing campaign for MSM, targeting the growing consumer trend in skin, hair, and nail health supplements.
-
Expects continued recovery in the European monogastric market following the finalization of antidumping duties on Chinese choline in late December 2025.
-
Maintains a capital allocation strategy prioritizing organic growth and strategic M&A, supported by a low net debt leverage ratio of 0.3.
-
Navigated a theoretical $20 million tariff impact, successfully reducing the actual effect to approximately $10 million through supply chain diversification.
-
Reported a 40 basis point decline in gross margin percentage primarily due to higher manufacturing input costs during the fourth quarter.
-
Increased the annual dividend by 10% to $0.96 per share, representing the 17th consecutive year of double-digit dividend growth.
-
Executed a share repurchase program of approximately 685,000 shares to offset equity incentive dilution and return capital to shareholders.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
